---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic impact on families"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic impact on families. Topics: Caregiver employment and caregiving time: 37 UK caregivers; Caregiving time by activity: caregiver diaries in eight European countries; Lost employment and out-of-pocket expenses: Canadian patient group input to the trofinetide review; Family strain: TSHA-102 sponsor caregiver survey, 323 caregivers in four countries. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Rett syndrome on Families

<a id="topic-2.2.1.8.3-1"></a>

### Caregiver employment and caregiving time: 37 UK caregivers

> “Average weekly time spent on caregiving tasks was 98.9 hours.”
> “Impacts of caregiving were described as sudden and life changing, including: restrictions to work (92%), social (92%) and daily (97%) activities which in turn contributed to strains in interpersonal relationships and finances. Only 14% of caregivers reported working full-time and 60% had stopped completely.”

Source: [Pimprikar et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/the-impact-of-caring-for-their-children-with-rett-syndrome-a-multi-method-study)

<a id="topic-2.2.1.8.3-2"></a>

### Caregiving time by activity: caregiver diaries in eight European countries

> “Care demands were substantial, with caregivers of adults spending an average of 41 hours per week providing emotional support alone, along with high time requirements for feeding (20 hours), washing and bathing (8 hours), and administering medication (5 hours).”
> “Time spent on many caregiving activities was highest in adults, including washing and bathing (7.8 hours per week), feeding (20.3 hours per week), administering medication (5.4 hours per week), helping with physio exercises (5.2 hours per week), and managing the equipment of the patient (4.8 hours per week)”

Source: [Pulles et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721293/)

<a id="topic-2.2.1.8.3-3"></a>

### Lost employment and out-of-pocket expenses: Canadian patient group input to the trofinetide review

> “The groups noted that Rett syndrome can be overwhelming, and patients may require constant care, impacting caregivers and families emotionally, physically, and financially. Caregivers may need to reduce or leave employment to provide full-time care, while also facing increased expenses related to medical care, therapies, specialized equipment, home modifications, and travel to specialized centres.”
> “Many caregivers have reported reducing work hours or leaving employment entirely to provide care, exacerbating financial strain.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

<a id="topic-2.2.1.8.3-4"></a>

### Family strain: TSHA-102 sponsor caregiver survey, 323 caregivers in four countries

> “Additionally, caregivers noted the impact of RTT symptoms on themselves (73%, n = 237) and other family members (33%, n = 105), as well as stress and strain on the family overall (52%, n = 167).”
> “Including financial strain, family dynamics, logistics of care, etc.”

Source: [Ben-Zeev et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13615242/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
